Proteomic analysis of androgen-independent growth in low and high passage human LNCaP prostatic adenocarcinoma cells

Journal of Biochemistry and Molecular Biology

Volumn 41, Issue 10, 2008, Pages 722-727

  Yun, Hee Youm ^a   Kim, Seyoon ^b   Young, Yil Bahk ^b   Tag, Keun Yoo ^a  

^a Eulji University School of Medicine   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

Androgen receptor; Gene silencing; LNCaP cell model; Prostate cancer; Proteomics

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; AR PROTEIN, HUMAN; CELL EXTRACT; DOXAZOSIN; MESSENGER RNA; PROTEOME; SMALL INTERFERING RNA; TUMOR PROTEIN;

ADENOCARCINOMA; ARTICLE; CELL CLONE; CELL PROLIFERATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HUMAN; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; PROTEOMICS; TUMOR CELL LINE; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ADENOCARCINOMA; ANDROGENS; CELL EXTRACTS; CELL LINE, TUMOR; CELL PROLIFERATION; CLONE CELLS; DOXAZOSIN; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MALE; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; PROTEOME; PROTEOMICS; RECEPTORS, ANDROGEN; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 55249104134     PISSN: 12258687     EISSN: 02191024     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Greenlee, R.T., Murray, T., Bolden, S. and Wingo, P.A. (2000) Cancer statistics, 2000. Cancer J. Clin. 50, 7-33.
2. Koivisto, P., Kolmer, M., Visakorpi, T. and Kallioniemi, O.P. (1998) Androgen receptor gene and hormonal therapy failure of prostate cancer. Am. J. Pathol. 152, 1-9.
3. Gittes, R.F. (1991) Carcinoma of the prostate. N. Engl. J. Med. 324, 236-245.
4. Quigley, C.A., De Bellis, B.A., Marschke, K.B., el-Awady, M.K., Wilson, E.M. and French, F.S. (1995) Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr. Rev. 16, 271-321.
5. Huggins, C. (1965) Two principles in endocrine therapy of cancers: hormone deprival and hormone interference. Cancer Res. 25, 1163-1167.
6. Catalona, W.J. (1994) Management of cancer of the prostate. N. Engl. J. Med. 331, 996-1004.
7. Westin. P. and Bergh, A. (1998) Apoptosis and other mechanisms in androgen ablation treatment and androgen independent progression of prostate cancer: a review. Cancer Detect. Prev. 22, 476-484.
8. Fournier, G. (1996) Treatment of hormone-refractory prostate carcinoma. Eur. Urol. 30 (Suppl. 1), 32-37.
9. Kyprianou. N., Bruckheimer, E.M. and Guo, Y. (2000) Cell proliferation and apoptosis in prostate cancer: significance in disease progression and therapy. Histol. Histopathol. 15, 1211-1223.
10. Honn, K.V., Aref, A., Chen, Y.Q., Cher, M.L., Crissman, J.D., Forman, J.D., Gao, X., Grignon, D., Hussain, M., Porter, A.T., Pontes, J.E., Powell, I., Redman, B., Sakr, W., Severson, R., Tang, D.G. and Wood, D.P. Jr. (1996) Prostate cancer: old problems and new approaches. Part III. Prevention and treatment. Pathol. Oncol. Res. 2, 276-292.
11. Wolf, D.A., Schulz, P. and Fittler, F. (1992) Transcriptional regulation of prostate kallikrein-like genes by androgen. Mol. Endocrinol. 6, 753-762.
12. Thalmann, G.N., Sikes, R.A., Wu, T.T., Degeorges, A., Chang, S.M., Ozen, M., Pathak, S. and Chung LW. (2000) LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate 44, 91-103.
13. Thalmann, G.N., Anezinis, P.E., Chang, S.M., Zhau, H.E., Kim, E.E., Hopwood, V.L., Pathak, S., von Eschenbach, A.C. and Chung, L.W. (1994) Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 54, 2577-2581.
14. Igawa, T., Lin, F.-F., Lee, M.-S., Karan, D., Batra, S.K. and Lin, M.F. (2002) Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate 50, 222-235.
15. Horoszewicz, J.S., Leong, S.S., Chu, T.M., Wajsman, Z.L., Friedman, M., Papsidero, L., Kim, U., Chai, L.S., Kakati, S., Arya, S.K. and Sandberg, A.A. (1980) The LNCaP cell line - a new model for studies on human prostatic carcinoma. Prog. Clin. Biol. Res. 37, 115-132.
16. Craft, N., Chhor, C., Tran, C., Belldegrun, A., DeKernion, J., Witte, O.N., Said, J., Reiter, R.E. and Sawyers, C.L. (1999) Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res. 59, 5030-5036.
17. Kyprianou, N. and Benning, C.M. (2000) Suppression of human prostate cancer cell growth by ?1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res. 60, 4550-4555.
18. Garrison, J.B. and Kyprianou, N. (2006) Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway. Cancer Res. 66, 464-472.
19. Yang, M. and Sytkowski, A.J. (1998) Differential expression and androgen regulation of the human selenium-binding protein gene HSP56 in prostate cancer cells. Cancer Res. 58, 3150-3153.
20. Gamble, S.C., Odontiadis, M., Waxman, J., Westbrrok, J.A., Dunn, M.J., Wait, R., Lam, E.W. and Bevan, C.L. (2004) Androgens target prohibitin to regulate proliferation of prostate cancer cells. Oncogene 23, 2996-3004.
21. Hood, B.L., Darfler, M.M., Guiel, T.G., Furusato, B., Lucas, D.A., Ringeisen, B.R., Sesterhenn, I.A., Conrads, T.P., Veenstra, T.D. and Krizman, D.B. (2005) Proteomic analysis of formalin-fixed prostate cancer tissue. Mol. Cell. Proteomics 4, 1741-1753.
22. Heinlein, C.A. and Chang, C. (2004) Androgen receptor in prostate cancer. Endocr. Rev. 25, 276-308.
23. Koivisto, P., Kononen, J., Palmberg, C., Tammela, T., Hyytinen, E., Isola, J., Trapman, J., Cleutjens, K., Noordzij, A., Visakorpi, T. and Kallioniemi, O.P. (1997) Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 57, 314-319.
24. Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinanen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J. and Kallioniemi, O.P. (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 9, 401-406.
25. Chen, C.D., Welsbie, D.S., Tran, C., Beak, S.H., Chen, R., Vessella, R., Rosenfeld, M.G. and Sawyers, C.L. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10, 33-39.
26. Unni, E., Sun, S., Nan, B., McPhaul, M.J., Cheskis, B., Mancini, M.A. and Marcelli. M. (2004) Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res. 64, 7156-7168.
27. Edwards, J., Krishna, N.S., Mukherjee, R., Watters, A.D., Underwood, M.A. and Bartlett, J.M. (2001) Amplification of the androgen receptor may not explain the development of androgen-independent prostate cancer. B.J.U. Int. 88, 633-637.
28. Rocchi, P., Jugpal, P., So, A., Sinneman, S., Ettinger, S., Fazli, L., Nelson, C. and Gleave, M. (2006) Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro. B.J.U. Int. 98, 1082-1089.
29. Rocchi, P., Beraldi, E., Ettinger, S., Fazli, L., Vessella, R.L., Nelson, C. and Gleave, M. (2005) Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res. 65, 11083-11093.
30. Pootrakul, L., Datar, R.H., Shi, S.-R., Cai, J., Hawes, D., Groshen, S.G., Lee, A.S. and Cote, R.J. (2006) Expression of stress response protein Grp78 is associated with the development of castration-resistant prostate cancer. Clin. Cancer Res. 12, 5987-5993.
31. Mossman, B.T. (1983) In vitro approaches for determining mechanisms of toxicity and carcinogenicity by asbestos in the gastrointestinal and respiratory tracts. Environ. Health Perspect. 53, 155-161.
32. Shim, J.H., Kim, Y.S. and Bahk, Y.Y. (2006) Proteome profile changes that are differentially regulated by lipid and protein phosphatase activities of tumor suppressor PTEN in PTEN-expressing U-87 MG human glioblastoma cells. Proteomics 6, 81-93.